Fujifilm (OTCMKTS:FUJIY) Stock Price Passes Above 200 Day Moving Average - Time to Sell?

Key Points

• Fujifilm Holdings Corp. recently saw its share price rise above its 200-day moving average, trading at $12.08 after hitting a high of $12.15.
• The company’s stock was downgraded from a "buy" to a "hold" rating by Wall Street Zen on May 23rd, indicating a potentially cautious outlook on the stock.
• Fujifilm reported a revenue of $5.08 billion for the last quarter, meeting analysts' expectations, with earnings per share of $0.15.

Fujifilm Holdings Corp. (OTCMKTS:FUJIY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $10.50 and traded as high as $12.15. Fujifilm shares last traded at $12.08, with a volume of 129,379 shares traded.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Fujifilm from a "buy" rating to a "hold" rating in a research report on Friday, May 23rd.

Fujifilm Stock Down 1.8%

The business has a 50 day moving average of $10.98 and a 200 day moving average of $10.55. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.48 and a quick ratio of 0.92. The firm has a market capitalization of $29.31 billion, a price-to-earnings ratio of 10.61, a price-to-earnings-growth ratio of 2.30 and a beta of 0.67.

Fujifilm (OTCMKTS:FUJIY - Get Free Report) last issued its earnings results on Wednesday, August 6th. The technology company reported $0.15 EPS for the quarter, meeting analysts' consensus estimates of $0.15. The business had revenue of $5.08 billion during the quarter, compared to analyst estimates of $760.41 billion. Fujifilm had a return on equity of 7.60% and a net margin of 7.93%. On average, equities analysts anticipate that Fujifilm Holdings Corp. will post 0.66 EPS for the current year.

About Fujifilm

FUJIFILM Holdings Corporation develops, manufactures, sells, and services imaging, healthcare, materials, and business innovation solutions worldwide. The company's Healthcare segment provides products and services, such as medical devices, biomedical contract development and manufacturing organization, pharmaceutical, regenerative medicine, and cosmetics and supplements in the areas of prevention, diagnosis, and treatment.